Healthcare

• Recce Pharmaceuticals upgraded its Australian R327G diabetic foot infection study to a pivotal Phase 3 trial with approval for up to 200 patients.

• Optiscan Imaging lodged an InSpecta regulatory dossier with the FDA’s Centre for Veterinary Medicine on 31 March 2026 and launched the device in the US veterinary market on 7 July 2026.

The shares changed hands around A$116 on 27 July, roughly 35 per cent above an early June low but far beneath a.79.

The first company to win FDA approval for a mesenchymal stromal cell therapy has finally banked a full year of product revenue. Its shares eased anyway, leaving investors to weigh a genuine commercial start against a long history of regulatory delay.

After years of regulatory grind and repeated dilution, OncoSil has strung together Australian approval, positive randomised trial data and a United States filing inside three months. The shares have given back ground anyway, on a screener reading no one can verify.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) attracted market attention during the afternoon trading session on 28 July 2026 after its shares advanced 1.89% to $33.74. The stock recorded a daily increase of $0.62, while maintaining a positive one-year performance with shares remaining …

Pro Medicus Ltd (ASX:PME) attracted market attention during trading on 28 July 2026 as its shares moved 0.17% higher to $162.51. The stock gained $0.27 during the session, reflecting modest positive movement amid broader strength across the healthcare sector.